Clinical Trial Update: AMPLIFY - D6571C00001 Duaklir USA Phase III Study [Phase 3]

View source ↗

Summary

Phase 3 study AMPLIFY (D6571C00001) for Duaklir in chronic obstructive pulmonary disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Duaklir (unknown)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-11-09